[go: up one dir, main page]

PE20090190A1 - Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18 - Google Patents

Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18

Info

Publication number
PE20090190A1
PE20090190A1 PE2008000506A PE2008000506A PE20090190A1 PE 20090190 A1 PE20090190 A1 PE 20090190A1 PE 2008000506 A PE2008000506 A PE 2008000506A PE 2008000506 A PE2008000506 A PE 2008000506A PE 20090190 A1 PE20090190 A1 PE 20090190A1
Authority
PE
Peru
Prior art keywords
combination
polypeptides
antibodies
ofatumumab
rituximab
Prior art date
Application number
PE2008000506A
Other languages
English (en)
Inventor
Zdenka Ludmila Jonak
Zdenka Haskova
Stephen H Trulli
John F Toso
Margaret N Whitacre
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20090190A1 publication Critical patent/PE20090190A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE UN POLIPEPTIDO DE IL-18 HUMANA (SEC ID Nº:16) Y UN ANTICUERPO ANTI-CD 20 TAL COMO RITUXIMAB U OFATUMUMAB. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE DIVERSOS CANCERES TALES COMO LEUCEMIAS, LINFOMAS, ENTRE OTROS
PE2008000506A 2007-03-23 2008-03-19 Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18 PE20090190A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
PE20090190A1 true PE20090190A1 (es) 2009-03-22

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008000506A PE20090190A1 (es) 2007-03-23 2008-03-19 Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
PE2008000532A PE20090184A1 (es) 2007-03-23 2008-03-24 Combinaciones del il-18 humana y anticuerpos monoclonales

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2008000532A PE20090184A1 (es) 2007-03-23 2008-03-24 Combinaciones del il-18 humana y anticuerpos monoclonales

Country Status (21)

Country Link
US (4) US20100196310A1 (es)
EP (3) EP2338514A1 (es)
JP (2) JP2010522200A (es)
KR (2) KR20100015798A (es)
CN (1) CN101678102A (es)
AR (2) AR065803A1 (es)
AU (2) AU2008231025A1 (es)
BR (2) BRPI0809079A2 (es)
CA (2) CA2681827A1 (es)
CL (2) CL2008000818A1 (es)
CR (2) CR10996A (es)
DO (2) DOP2009000208A (es)
EA (2) EA200970885A1 (es)
IL (2) IL200525A0 (es)
MA (2) MA31264B1 (es)
MX (2) MX2009010271A (es)
NZ (1) NZ579179A (es)
PE (2) PE20090190A1 (es)
SG (1) SG171674A1 (es)
TW (2) TW200906436A (es)
WO (2) WO2008118736A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151044A0 (en) * 2000-02-10 2003-04-10 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
HRP20192254T1 (hr) 2014-04-25 2020-03-06 Pierre Fabre Medicament Konjugat antitijela i lijeka i njegova upotreba u liječenju karcinoma
RU2692563C2 (ru) 2014-04-25 2019-06-25 Пьер Фабр Медикамент Конъюгат антитела против igf-1r с лекарственным средством и его применение для лечения рака
NZ729395A (en) * 2014-08-07 2018-04-27 Hyogo College Medicine Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
WO2016126615A1 (en) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2022115946A1 (en) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists
WO2025033330A1 (ja) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 キマーゼ阻害剤と免疫療法の併用による抗腫瘍療法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692536B1 (en) 1994-07-14 2000-11-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo IFN-Y production inducing protein and monoclonal antibody of the same
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
PL208592B1 (pl) * 2000-06-15 2011-05-31 Smithkline Beecham Corp Sposób wytwarzania aktywnego ludzkiego polipeptydu IL-18 z ludzkiego polipeptydu prekursora IL-18
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
AU2003208415B2 (en) * 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
CN1646161A (zh) * 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
ATE497778T1 (de) * 2002-09-16 2011-02-15 Agennix Inc Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
KR20050073488A (ko) * 2002-10-08 2005-07-13 이뮤노메딕스, 인코오포레이티드 Ⅲ종 항-ｃｅａ 단클론 항체들 및 치료제들을 이용한 조합치료법
NZ568769A (en) * 2002-10-17 2010-04-30 Genmab As Human monoclonal antibodies against CD20
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
DE602004025799D1 (de) * 2003-04-15 2010-04-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
EP1648512A4 (en) * 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
WO2006111524A2 (en) * 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
US9580506B2 (en) * 2005-07-21 2017-02-28 Genmab A/S Potency assays for antibody drug substance binding to an Fc receptor
AU2007272330A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
JP2010503680A (ja) * 2006-09-14 2010-02-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヒトｉｌ−１８による調節ｔ細胞のモジュレーション
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Also Published As

Publication number Publication date
CN101678102A (zh) 2010-03-24
DOP2009000220A (es) 2009-10-31
NZ579179A (en) 2011-12-22
MA31264B1 (fr) 2010-03-01
DOP2009000208A (es) 2010-03-31
CL2008000818A1 (es) 2008-09-26
WO2008118733A2 (en) 2008-10-02
AU2008231025A1 (en) 2008-10-02
EP2129398A4 (en) 2010-04-21
EP2129398A1 (en) 2009-12-09
CR10996A (es) 2009-11-12
IL200863A0 (en) 2010-05-17
US20090035258A1 (en) 2009-02-05
EP2136841A4 (en) 2010-07-07
IL200525A0 (en) 2010-04-29
KR20100015798A (ko) 2010-02-12
EP2338514A1 (en) 2011-06-29
JP2010522200A (ja) 2010-07-01
MA31265B1 (fr) 2010-03-01
US20080274078A1 (en) 2008-11-06
AR065818A1 (es) 2009-07-01
EA200970885A1 (ru) 2010-02-26
US20100196310A1 (en) 2010-08-05
MX2009010269A (es) 2009-10-12
EP2136841A2 (en) 2009-12-30
JP2010522239A (ja) 2010-07-01
BRPI0809079A2 (pt) 2019-03-06
CR11075A (es) 2010-03-22
CA2681827A1 (en) 2008-10-02
EA200970884A1 (ru) 2010-04-30
AR065803A1 (es) 2009-07-01
TW200904469A (en) 2009-02-01
CL2008000842A1 (es) 2008-10-17
WO2008118736A1 (en) 2008-10-02
US20100111945A1 (en) 2010-05-06
TW200906436A (en) 2009-02-16
PE20090184A1 (es) 2009-03-22
KR20100014530A (ko) 2010-02-10
AU2008231114A1 (en) 2008-10-02
MX2009010271A (es) 2009-10-12
CA2681851A1 (en) 2008-10-02
WO2008118733A3 (en) 2008-11-27
BRPI0808943A2 (pt) 2014-08-26
SG171674A1 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
PE20090190A1 (es) Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
PE20140382A1 (es) Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
MX2025007532A (es) Receptores de antigenos quimericos para el tratamiento del cancer
PE20191106A1 (es) Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1
PE20091328A1 (es) Formulacion de anticuerpo
CR7875A (es) Variantes de inmunoglobina y usos de esto
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
PE20081456A1 (es) Anticuerpo monoclonal contra nectina 2
CO6331291A2 (es) Peptidos de señalizacion de la crkl
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
AR083293A1 (es) Agentes de union a cd33
PE20142114A1 (es) Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
AR075029A1 (es) Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
PE20110771A1 (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CR8600A (es) Sistema de transporte biologico multicomponente
PE20130589A1 (es) Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
SG10201407329RA (en) Modified vasoactive intestinal peptides
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
MA32288B1 (fr) Nouveaux anticorps utiles pour le traitement du cancer
CL2011002862A1 (es) Uso de perhexilina o una sal farmaceuticamente aceptable de la misma para preparar un medicamento util en el tratamiento de miocardiopatia hipertrofica (mch).
AU7866201A (en) NK cells activating receptors and their therapeutic and diagnostic uses
UA85574C2 (uk) Ендопаразитоцидний засіб для місцевого застосування

Legal Events

Date Code Title Description
FD Application declared void or lapsed